Sudan Loganathan
Stock Analyst at Stephens
(3.98)
# 1,775
Out of 5,085 analysts
36
Total ratings
57.6%
Success rate
16.9%
Average return
Main Sectors:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADCT ADC Therapeutics | Rated: Buy | $8 → $5 | $1.62 | +208.64% | 3 | Jun 4, 2026 | |
| PVLA Palvella Therapeutics | Initiated Coverage: Buy | $220 | $147.47 | +49.18% | 1 | May 11, 2026 | |
| IMNM Immunome | Rated: Buy | $33 → $30 | $18.76 | +59.91% | 3 | Mar 4, 2026 | |
| KYMR Kymera Therapeutics | Reiterated: Buy | $110 → $100 | $122.51 | -18.37% | 3 | Mar 2, 2026 | |
| ARVN Arvinas | Reiterated: Buy | $15 → $18 | $7.60 | +136.84% | 4 | Feb 25, 2026 | |
| PYXS Pyxis Oncology | Reiterated: Buy | $13 → $8 | $1.98 | +304.04% | 2 | Nov 24, 2025 | |
| CADL Candel Therapeutics | Initiated Coverage: Buy | $15 | $8.67 | n/a | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Upgraded: Buy | $4 → $6 | $3.40 | n/a | 2 | Sep 15, 2025 | |
| FTH Faeth Therapeutics | Reiterated: Buy | $5 → $35 | $19.20 | n/a | 2 | Jun 30, 2025 | |
| EXEL Exelixis | Upgraded: Buy | $29 → $60 | $66.28 | n/a | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $30 | $27.26 | n/a | 2 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $1 | - | n/a | 2 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $5 | $1.38 | n/a | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $15 | $10.87 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $51 | $33.96 | n/a | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $25 | $3.88 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $25 | $14.86 | n/a | 1 | May 13, 2024 |
ADC Therapeutics
Jun 4, 2026
Rated: Buy
Price Target: $8 → $5
Current: $1.62
Upside: +208.64%
Palvella Therapeutics
May 11, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $147.47
Upside: +49.18%
Immunome
Mar 4, 2026
Rated: Buy
Price Target: $33 → $30
Current: $18.76
Upside: +59.91%
Kymera Therapeutics
Mar 2, 2026
Reiterated: Buy
Price Target: $110 → $100
Current: $122.51
Upside: -18.37%
Arvinas
Feb 25, 2026
Reiterated: Buy
Price Target: $15 → $18
Current: $7.60
Upside: +136.84%
Pyxis Oncology
Nov 24, 2025
Reiterated: Buy
Price Target: $13 → $8
Current: $1.98
Upside: +304.04%
Candel Therapeutics
Oct 28, 2025
Initiated Coverage: Buy
Price Target: $15
Current: $8.67
Upside: n/a
C4 Therapeutics
Sep 15, 2025
Upgraded: Buy
Price Target: $4 → $6
Current: $3.40
Upside: n/a
Faeth Therapeutics
Jun 30, 2025
Reiterated: Buy
Price Target: $5 → $35
Current: $19.20
Upside: n/a
Exelixis
Jun 24, 2025
Upgraded: Buy
Price Target: $29 → $60
Current: $66.28
Upside: n/a
Apr 9, 2025
Reiterated: Buy
Price Target: $20 → $30
Current: $27.26
Upside: n/a
Mar 24, 2025
Downgraded: Hold
Price Target: $8 → $1
Current: -
Upside: n/a
Nov 19, 2024
Reiterated: Buy
Price Target: $25 → $5
Current: $1.38
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $15
Current: $10.87
Upside: n/a
Nov 18, 2024
Initiated Coverage: Buy
Price Target: $51
Current: $33.96
Upside: n/a
Nov 7, 2024
Initiated Coverage: Hold
Price Target: $25
Current: $3.88
Upside: n/a
May 13, 2024
Rated: Buy
Price Target: $25
Current: $14.86
Upside: n/a